Soligenix, Inc. (OTCBB: SNGX) is a clinical stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. Soligenix’s therapeutics segment is dedicated to the development of products for orphan diseases and areas of unmet medical need such as oral mucositis, pediatric Crohn’s disease, acute radiation enteritis, and Graft-versus-Host disease (GVHD). Its vaccines/biodefense segment is developing vaccines and therapeutics for military and civilian applications in the areas of ricin exposure, anthrax exposure, gastrointestinal acute radiation syndrome, and melioidosis. For more information, visit the company’s website at www.soligenix.com